Payment overview · 2025
General Payments
$670.35
25 reported records · 13 companies
Healthcare provider profile · identity verified
Edgar R Blecker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SEBASTIAN, FL · NPI 1952388100
Verified facts
What the public records show
CMS Open Payments records show Edgar R Blecker, M.D. received $670.35 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $257.72 | 38.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $88.83 | 13.2% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $53.87 | 8.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.61 | 7.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.06 | 5.4% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $35.29 | 5.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $28.03 | 4.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.01 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.26 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.75 | 3.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.89 | 2.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.19 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.84 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $670.35 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.72 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.10 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.10 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $53.87 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.61 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $28.03 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
280 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1341 | 440 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 972 | 327 |
| Lisinopril | Lisinopril | 731 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 723 | 238 |
| Metformin Hcl | Metformin Hcl | 680 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 177 |
| Losartan Potassium | Losartan Potassium | 497 | 167 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 437 | 96 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 388 | 76 |
| Gabapentin | Gabapentin | 377 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 128 |
| Furosemide | Furosemide | 364 | 129 |
| Trazodone Hcl | Trazodone Hcl | 332 | 108 |
| Omeprazole | Omeprazole | 320 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 115 |
| Metoprolol Tartrate | Metoprolol Tartrate | 309 | 99 |
| Eliquis | Apixaban | 293 | 74 |
| Jardiance | Empagliflozin | 280 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 105 |
| Azithromycin | Azithromycin | 267 | 169 |
| Duloxetine Hcl | Duloxetine Hcl | 259 | 75 |
| Alprazolam | Alprazolam | 258 | 57 |
| Clonazepam | Clonazepam | 239 | 54 |
| Benazepril Hcl | Benazepril Hcl | 231 | 69 |
| Temazepam | Temazepam | 218 | 61 |
| Tramadol Hcl | Tramadol Hcl | 210 | 56 |
| Carvedilol | Carvedilol | 200 | 62 |
| Finasteride | Finasteride | 182 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 51 |
| Allopurinol | Allopurinol | 167 | 55 |
| Oxycodone Hcl | Oxycodone Hcl | 159 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 156 | 118 |
| Simvastatin | Simvastatin | 155 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 59 |
| Alendronate Sodium | Alendronate Sodium | 141 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 73 |
| Ezetimibe | Ezetimibe | 138 | 39 |
| Meloxicam | Meloxicam | 136 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 48 |
| Diazepam | Diazepam | 134 | 33 |
| Donepezil Hcl | Donepezil Hcl | 121 | 38 |
| Glipizide Er | Glipizide | 117 | 39 |
| Atenolol | Atenolol | 114 | 38 |
| Potassium Chloride | Potassium Chloride | 114 | 36 |
| Montelukast Sodium | Montelukast Sodium | 106 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 34 |
| Ozempic | Semaglutide | 103 | 30 |
| Glipizide | Glipizide | 100 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 97 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 34 |
| Sertraline Hcl | Sertraline Hcl | 93 | 36 |
| Metformin Hcl Er | Metformin Hcl | 89 | 28 |
| Spironolactone | Spironolactone | 89 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 18 |
| Levofloxacin | Levofloxacin | 85 | 64 |
| Prednisone | Prednisone | 84 | 43 |
| Famotidine | Famotidine | 83 | 32 |
| Pregabalin | Pregabalin | 82 | 22 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 79 | 54 |
| Eszopiclone | Eszopiclone | 79 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 26 |
| Acyclovir | Acyclovir | 72 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 35 |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 18 |
| Glimepiride | Glimepiride | 64 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 63 | 26 |
| Valsartan | Valsartan | 63 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 62 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 61 | 11 |
| Buspirone Hcl | Buspirone Hcl | 61 | 23 |
| Methadone Hcl | Methadone Hcl | 59 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 17 |
| Farxiga | Dapagliflozin Propanediol | 55 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 28 |
| Xarelto | Rivaroxaban | 53 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 17 |
| Clonidine Hcl | Clonidine Hcl | 50 | 20 |
| Lorazepam | Lorazepam | 49 | 17 |
| Baclofen | Baclofen | 48 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 18 |
| Bupropion Xl | Bupropion Hcl | 46 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 14 |
| Folic Acid | Folic Acid | 44 | 17 |
| Levetiracetam | Levetiracetam | 44 | 11 |
| Nitroglycerin | Nitroglycerin | 44 | 20 |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 14 |
| Metronidazole | Metronidazole | 41 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Mirtazapine | Mirtazapine | 40 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Hydrocortisone | Hydrocortisone | 37 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 13 |
| Estradiol | Estradiol | 36 | 14 |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Enalapril Maleate | Enalapril Maleate | 35 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 13 |
| Bupropion Hcl | Bupropion Hcl | 34 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | 12 |
| Methotrexate | Methotrexate Sodium | 33 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | 11 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 16 |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 16 |
| Lactulose | Lactulose | 30 | suppressed |
| Naproxen | Naproxen | 30 | 17 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 16 |
| Linzess | Linaclotide | 29 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 22 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | 11 |
| Nystatin | Nystatin | 22 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 16 |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 11 |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Ofev | Nintedanib Esylate | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.35 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, CAPLYTA, CHARTIS CATHETER, GVOKE HYPOPEN, INSPIRE, Leqembi, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PULMONX CHARTIS TABLET CONSOLE, REPATHA, TRELEGY ELLIPTA, VYNDAQEL, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error